Expression of prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), human kallikrein 2 (hK2), prostate stem cell antigen (PSCA), and differential display code 3 (DD3) in 2215 LNs isolated from 120 patients with localized prostate cancer were assessed by fully quantitative real-time RT-PCR.
This study compared <sup>68</sup>Gallium-prostate-specific-membrane-antigen based Positron-emission-tomography (<sup>68</sup>Ga-PSMA-PET) and <sup>99metastable</sup>technetium-3,3-diphospho-1,2-propanedicarbonacid (<sup>99m</sup>Tc-DPD-SPECT) in performing skeletal staging in prostate cancer (PC) patients and evaluated the additional value of the information from low-dose-computed tomography (CT).
The first reports on safety and efficacy of Lu-PSMA have been retrospective series of men with advanced prostate cancer who previously failed conventional therapies and received Lu-PSMA on compassionate basis.
<b>Methods:</b><sup>68</sup>Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (<i>n</i> = 25), primary diagnosis (<i>n</i> = 10), biochemical persistence after primary therapy (<i>n</i> = 5), or staging of known metastatic disease (<i>n</i> = 10).
Moreover, absence of appropriate biomarker is one of the major challenges for prostate specific membrane antigen negative (PSMA (-)) prostate cancer therapy.
Our results demonstrate the therapeutic potential of specific-oncolysis and suicide gene therapy for AI-PSA/PSMA-positive prostate cancer gene therapy.
For example, a phase III randomized, controlled trial provided unequivocal evidence of the effectiveness of 177Lu-DOTATATE for treatment of neuroendocrine tumors, and there have been multiple reports of the benefits of prostate-specific membrane antigen targeted PET imaging and radio-ligand therapy in prostate cancer.
In the present study, <sup>64</sup> Cu-PSMA-617-PET demonstrated to be feasible for imaging prostate cancer for both the primary tumor site and metastases.
The semi-quantitative parameters of <sup>68</sup>Ga-PSMA-617 PET/CT were used to establish a univariate logistic regression model for high-risk prostate cancer and its metastatic risk, and to evaluate the diagnostic efficacy of the predictive model.
The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts.
To identify locations of recurrence after radical prostatectomy (RP) with prostate-specific antigen (PSA) <2 by Gallium-68 prostate-specific membrane antigen (PSMA)-11 Positron Emission Tomography (PET) imaging, and to determine whether standard nodal radiation fields would cover the location of prostate cancer recurrence.
For evaluating the advantages and disadvantages and the comparability, we conducted a prospective head-to-head comparison on F-fluciclovine and Ga-PSMA-11 in patients with biochemical recurrence of PCa.
Conclusion This study found that <sup>68</sup>Ga-PSMA-11 PET can be used to identify prostate cancer, while MR imaging provides detailed anatomic guidance.
A limitation of using <sup>68</sup>Ga-labeled prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA) for detection and staging of prostate cancer is a frequently observed halo artifact around the urinary bladder caused by inaccurate scatter correction (SC) of PET data.
A total of 139 patients underwent Ga-68-PSMA-11 PET imaging for prostate cancer: 47 non-time-of-flight (non-TOF) PET/computed tomography, 51 PET/magnetic resonance imaging (MRI) using the standard TOF scatter correction algorithm, and 41 PET/MRI using an improved TOF scatter correction algorithm.
Prostate-specific membrane antigen (PSMA), an established enzyme-biomarker for prostate cancer, has attracted considerable attention as a target for imaging and therapeutic applications.
We consider that these findings provide a basis for the development of systemically delivered PSMA/iNOS or hOC/iNOS targeting early stage and advanced prostate cancer.
Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [<sup>68</sup>Ga]PSMA I&T and comparison with published data of [<sup>68</sup>Ga]PSMA HBED-CC.
The aim of this study was to evaluate the diagnostic value of PSMA PET/CT in the diagnosis of recurrent PCa with low prostate-specific antigen (PSA) levels.
By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that <sup>68</sup>Ga PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer.